Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05727228
Other study ID # 2704
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 27, 2023
Est. completion date February 2027

Study information

Verified date February 2023
Source University of Aarhus
Contact mette tranberg, post doc
Phone 40113676
Email mettrani@rm.dk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

- To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load as triage markers in post-menopausal HPV-screen-positive women aged 50-64 years in the organized screening program to predict the risk of developing CIN2+. (work package 1) - To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load six months after cervical excision to predict the long-term risk of residual/recurrent CIN2+ lesions among women aged 23-64 (work-package 2)


Description:

As HPV-positive women may have a transient infection which would be cleared with treatment, triage of HPV-positive women are needed to decrease the colposcopy referral. Liquid-based cytology (hereinafter cytology) are often used as triage for HPV-positive women. HPV 16/18 are the predominant HPV types in younger women and are for all aged referred directly for colposcopy. However as women age, hrHPV other types become more prevalent(10) and these types are triaged with cytology. However, as cytology undergo subjective interpretation and as it may have a decreased sensitivity in with increasing age(11, 12) cytology may not be the most optimal triage marker in postmenopausal women. p16/Ki67 dual stain cytology (hereinafter DS) is another triage marker. p16 is a cell-cycle regulator protein and Ki67 is a proliferation-associated protein which under normal circumstances are mutual exclusive. Thus, in an HPV-transformed cell co-expression of p16 and Ki67 indicates cell deregulation and increased risk of cervical precancer.(13) In several studies DS have shown better sensitivity and negative predictive value (NPV) as compared to cytology in triaging HPV-positive women(14-17) and women with low-grade cytology (ASC-US and LSIL)(18-20). Methylation of HPV-positive women benefits from a more objective evaluation than both cytology and DS and has in shown promising results in triaging HPV-positive women.(21) Most studies on DS and methylation have however, been conducted in younger women and studies evaluation the performance in postmenopausal women are needed. Women diagnosed with CIN2+ undergo excisional treatment removing the lesions and thereby reducing the woman's risk of developing cervical cancer. The most frequently used method is loop electrosurgical excision procedure (LEEP). Despite treatment, women previously diagnosed with CIN3+ lesion are at greater risk of developing cervical cancer with the risk increasing with increasing age.(22) Surveillance after LEEP consist of test-of cure (i.e. cytology and HPV test) six months after LEEP in several countries.(23-27) Treatment of CIN2+ is however, not always successful and residual or recurrent high-grade disease (CIN2+) occurs on average in 8% (ranging from 4% to 18%) of treated women, with the majority of treatment failure occurring mainly the first two post-operative years.(28, 29) Persistent HPV infection and positive margins after LEEP are risk factors for residual or recurrent disease after LEEP(28). However, not all women are at the same risk of recurrent disease, but still managed the same way as women at higher risk and therefore a future risk-stratification are needed to individualize the follow-up pathways. Moreover, introduction of a risk-stratification in the follow-up pathway may also decrease the number of open-ended follow-up pathways. In a recent study in HPV-positive women 60-64 years only 26% had follow-up as recommended.(30)


Recruitment information / eligibility

Status Recruiting
Enrollment 5000
Est. completion date February 2027
Est. primary completion date February 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 23 Years to 64 Years
Eligibility Inclusion Criteria: - HPV-screen-positive (aged 50-64) - Women who undergo test-of-cure (i.e. HPV and cytology) six months after LEEP in Central Denmark Region (aged 23-64) - Women who undergo follow-up test (i.e. HPV and cytology) 12 months after LEEP - A valid cytology-triage result (aged 23-64) Exclusion Criteria: - Listed in the registry as a person who have rejected to participate in research - Invalid cytology and HPV result six months after LEEP - No residual material available

Study Design


Intervention

Other:
cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,
p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.

Locations

Country Name City State
Denmark Department of Pathology Randers Central Denmark Region

Sponsors (2)

Lead Sponsor Collaborator
University of Aarhus Randers Regional Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of women with CIN2+ diagnosed in either cervical biopsies or cone biopsy The detection of underlying CIN2 or worse at baseline ( within 3 months after index sample)
Primary The number of women with CIN2+ diagnosed in either cervical biopsies or cone biopsy The detection of underlying CIN2 or worse at follow-up ( 1.5 years after index sample)
Primary The number of women with CIN3+ diagnosed in either cervical biopsies or cone biopsy The detection of underlying CIN3 or worse at baseline ( within 3 months after index sample)
Primary The number of women with CIN3+ diagnosed in either cervical biopsies or cone biopsy The detection of underlying CIN3 or worse at follow-up (1.5 years after index sample)
Secondary Clinical accuracy (sensitivity and specificity of each triage marker and in different combinations) sensitivity to detect underlying CIN2+ and specificity to exclude underlying CIN2+ at baseline (within 3 months after index sample)
Secondary Clinical accuracy (sensitivity and specificity of each triage marker and in different combinations) sensitivity to detect underlying CIN2+ and specificity to exclude underlying CIN2+ at follow-up (1.5 years after index sample)
Secondary HPV genotype distribution We will measure the distribution of hrHPV types among these older women at baseline (within 3 months after index sample)
Secondary DS positivity rate We will measure the DS positivity rate among these older women at baseline (within 3 months after index sample)
See also
  Status Clinical Trial Phase
Recruiting NCT04067882 - Validation of the Genetic Signature 354849 as a Prognostic Method
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Recruiting NCT05743517 - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) N/A
Completed NCT05234112 - Prevention and Screening Towards Elimination of Cervical Cancer N/A
Completed NCT04258553 - Thiol Disulfide Balance in Cervix Cancer
Completed NCT03956498 - Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy N/A
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Completed NCT00379743 - Partnership for Healthy Seniors N/A
Completed NCT00509444 - Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial Phase 3
Recruiting NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. Phase 1
Recruiting NCT06116019 - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Active, not recruiting NCT06452004 - Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) N/A
Recruiting NCT04651127 - Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT06010875 - A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors Phase 1
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02997553 - Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Phase 3
Terminated NCT02233387 - PET CT With HX4 in Cervix Cancer Phase 2
Completed NCT01766284 - Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix N/A